A 6-month Study to Evaluate Sulforaphane Effects in Schizophrenia Patients

• Status: Not yet recruiting
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The goal of the study is to investigate whether adding sulforaphane will benefit the negative symptoms and cognitive function in individuals who have schizophrenia.

This study will compare the sulforaphane with placebo. There is a thirty percent change (less than half) of receiving the placebo. The purpose of including placebo is to judge if the outcome is related to the study medication rather than other reasons.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Central South University
• Treatments: Sulforafan; Sulforaphane

Criteria

Inclusion Criteria:

• 1. Meet The Diagnostic and Statistical Manual (DSM-5) diagnostic criteria for schizophrenia 2. First onset or duration of illness less than 30 years with current symptoms in a stable condition 3. Male and female with aged 17 to 50 years 4. an item of PANSS negative symptoms >3 scores. 5. Signed the study consent for participation.

Exclusion Criteria:

• 1. having history of substance dependence or abuse or whose symptoms are caused by the other diagnosable mental disorders; 2. having history of traumatic brain injury, seizures or other known neurological or organic diseases of the central nervous system; 3. taking antidepressants, stimulants, mood stabilizer or accepts electricity shock treatment; 4. having current suicidal or homicidal thoughts or any safety concern by research staff that cannot be manage in an inpatient setting; 5. taking dementia-related drugs, minocycline, and other drugs that could affect cognitive function.

6. the routine blood tests showing significant abnormal renal, liver function or other metabolic results.

6. pregnant or lactating women.